MTCYBP20

Across TCGA pan-cancer cohorts, MTCYBP20 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MTCYBP20’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MTCYBP20 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCYBP20 is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.

LIHC are the cancer types where MTCYBP20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCYBP20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	−0.008	.026	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

MTCYBP20–LIHC

Open the LIHC breakdown →